The impact of biosimilars can reduce biologic therapy costs with comparable clinical outcomes.
Respiratory syncytial virus (RSV) can be especially serious for infants and older adults, but vaccines can help reduce the burden on at-risk populations.
Healthcare decisions made from data-driven insights are personal and proactive.
Changes to guidance from the WHO and CDC should strengthen preparedness and response to future potential pandemic diseases.
Emergency departments will need specialized equipment and staff to ensure pediatric readiness for improved survival.
FDA-mandated boxed warnings highlighting potential risks and clinicians performing comprehensive risk evaluations can help prevent the infrequent adverse drug reactions with IG products.
This revolutionary technology shows promise for addressing a myriad of challenges in medicine, but ethical dilemmas remain.
Can anti-SARS-CoV-2 antibodies in the plasma supply protect against COVID infection in
immunodeficient patients? Research suggests otherwise.
Known as liquid gold, human plasma is proving to be a valuable ally in the fight against cancer.